The study will be conducted in three periods:~Screening Period (up to 4 weeks) during which patient eligibility will be assessed;~Double-blind Treatment Period (4 weeks) in which all patients will be randomized to receive placebo or lenrispodun 30 mg/day in 1:1 ratio.~Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.